01828nas a2200229   4500008004100000024000700041245012100048210006900169260001500238300001200253490000700265520115200272653000901424653001501433653001601448653001101464653001401475100002101489700002101510700002701531856004001558       2023                        eng d  a1300aThe Antidepressant Effect of Fluoxetine and Mozart K448 Combination Therapy on Hippocampal Serotonin and BDNF Levels0 aAntidepressant Effect of Fluoxetine and Mozart K448 Combination   cApril 2023  a325-3280 v153 a<p class="rtejustify">Despite the use of fluoxetine as a first-line therapy, some patients do not show a good therapeutic effect. Effective antidepressant therapy will reverse the low serotonin and BDNF levels found in depression. Mozart K. 448 was reported to yield a good therapeutic effect for depression. Based on findings, the combination of Mozart K. 448 and fluoxetine as a therapy for depression is very rare. Therefore, this study aimed to determine the effect of the combined therapy of fluoxetine and Mozart K. 448 on hippocampal serotonin and BDNF levels in an animal model of depression under CUMS conditions. In this study, the animal model of depression was administered three different treatments, i.e. fluoxetine, Mozart, or fluoxetine-Mozart combined therapy, respectively. Hippocampal serotonin and BDNF levels were assessed after 21 days of treatment. Statistical analysis was then carried out using T-test or Mann-Whitney test and ANOVA or Kruskal-Wallis. The fluoxetine-Mozart group has higher BDNF levels, but lower serotonin levels compared to other groups with values of 1,694±0.215 and 44,533±3,275, respectively.</p>
10aBDNF10aFluoxetine10aHippocampus10aMozart10aSerotonin1 aPangemanan, Lisa1 aIrwanto, Irwanto1 aMaramis, Margarita, M.  uhttps://www.phcogj.com/article/2002